Plasma IL-6 Levels following Corticosteroid Therapy as an Indicator of ICU Length of Stay in Critically ill COVID-19 Patients
Intensive Care Unit (ICU) admissions and mortality in severe COVID-19 patients are driven by “cytokine storms” and acute respiratory distress syndrome (ARDS). Interim clinical trial results suggest that the corticosteroid dexamethasone displays superior 28-day survival in severe COVID-19 patients requiring ventilation or oxygen. Among 16 patients with plasma IL-6 measurement post-corticosteroid administration, a higher proportion of patients with an IL-6 value over 10 pg/mL have worse outcomes (i.e. ICU Length of Stay > 15 days or death) when compared to 41 patients treated with non-corticosteroid drugs including antivirals, tocilizumab, azithromycin, and hydroxychloroquine (p-value = 0.0024). Given this unexpected clinical association between post-corticosteroid IL-6 levels and COVID-19 severity, we hypothesized that the Glucocorticoid Receptor (GR or NR3C1) may be coupled to IL-6 expression in specific cell types that govern cytokine release syndrome (CRS). Examining single cell RNA-seq data from bronchoalveolar lavage fluid of severe COVID-19 patients and nearly 2 million human cells from a pan-tissue scan shows that alveolar macrophages, smooth muscle cells, and endothelial cells co-express both NR3C1 and IL-6. The mechanism of Glucocorticoid Receptor (GR) agonists mitigating pulmonary and multi-organ inflammation in some COVID-19 patients with respiratory failure, may be in part due to their successful antagonism of IL-6 production within lung macrophages and vasculature..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 13. Jan. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Awasthi, Samir [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.07.02.20144733 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018283322 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018283322 | ||
| 003 | DE-627 | ||
| 005 | 20230429093959.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200706s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.07.02.20144733 |2 doi | |
| 035 | |a (DE-627)XBI018283322 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.07.02.20144733 | ||
| 035 | |a (biorXiv)10.1101/2020.07.02.20144733 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Awasthi, Samir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma IL-6 Levels following Corticosteroid Therapy as an Indicator of ICU Length of Stay in Critically ill COVID-19 Patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Intensive Care Unit (ICU) admissions and mortality in severe COVID-19 patients are driven by “cytokine storms” and acute respiratory distress syndrome (ARDS). Interim clinical trial results suggest that the corticosteroid dexamethasone displays superior 28-day survival in severe COVID-19 patients requiring ventilation or oxygen. Among 16 patients with plasma IL-6 measurement post-corticosteroid administration, a higher proportion of patients with an IL-6 value over 10 pg/mL have worse outcomes (i.e. ICU Length of Stay > 15 days or death) when compared to 41 patients treated with non-corticosteroid drugs including antivirals, tocilizumab, azithromycin, and hydroxychloroquine (p-value = 0.0024). Given this unexpected clinical association between post-corticosteroid IL-6 levels and COVID-19 severity, we hypothesized that the Glucocorticoid Receptor (GR or NR3C1) may be coupled to IL-6 expression in specific cell types that govern cytokine release syndrome (CRS). Examining single cell RNA-seq data from bronchoalveolar lavage fluid of severe COVID-19 patients and nearly 2 million human cells from a pan-tissue scan shows that alveolar macrophages, smooth muscle cells, and endothelial cells co-express both NR3C1 and IL-6. The mechanism of Glucocorticoid Receptor (GR) agonists mitigating pulmonary and multi-organ inflammation in some COVID-19 patients with respiratory failure, may be in part due to their successful antagonism of IL-6 production within lung macrophages and vasculature. | ||
| 700 | 1 | |a Wagner, Tyler |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatakrishnan, AJ |e verfasserin |4 aut | |
| 700 | 1 | |a Puranik, Arjun |e verfasserin |4 aut | |
| 700 | 1 | |a Hurchik, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Vineet |e verfasserin |4 aut | |
| 700 | 1 | |a Conrad, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkup, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Arunachalam, Raman |e verfasserin |4 aut | |
| 700 | 1 | |a O’Horo, John |e verfasserin |4 aut | |
| 700 | 1 | |a Kremers, Walter |e verfasserin |4 aut | |
| 700 | 1 | |a Kashyap, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Morice, William |e verfasserin |4 aut | |
| 700 | 1 | |a Halamka, John |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Amy W. |e verfasserin |4 aut | |
| 700 | 1 | |a Faubion, William A. |e verfasserin |4 aut | |
| 700 | 1 | |a Badley, Andrew D. |e verfasserin |4 aut | |
| 700 | 1 | |a Gores, Gregory J. |e verfasserin |4 aut | |
| 700 | 1 | |a Soundararajan, Venky |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 13. Jan. |
| 773 | 1 | 8 | |g year:2021 |g day:13 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.07.02.20144733 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 13 |c 01 | ||
| 953 | |2 045F |a 570 | ||